Decentralized drug price control starts first in Guangdong*

On November 6, the news said that the rules for drug trading in Guangdong Province may change. Yesterday, the news was confirmed.

On November 10, the Guangdong Provincial Health and Family Planning Commission released on the official website of the “Draft Opinions on Soliciting Opinions on Amendments to the Measures for Drug Trading Rules of Medical Institutions in Guangdong Province” (hereinafter referred to as the “Exposure Draft”). In the consultation draft, amendments were made to the trading methods for base drugs and non-base drugs, drug procurement and distribution, and drug settlement and supervision.

As a major province of medicine, the bidding policy of Guangdong Province has attracted much attention. In May last year, Guangdong Province plans to reform the current procurement model for centralized tendering of pharmaceuticals and turn it into online trading on a third-party drug electronic trading platform.

However, the five major associations, including the China Association of Pharmaceutical Enterprise Management Association, put forward suggestions and suggestions to Guangdong, but only a few of the amendments were adopted. The revising of this plan, especially for the revision of low-price drug related policies, is more in line with the recommendations made by the five major associations at that time, and played a decisive role in the allocation of drug resources in the market mechanism and reduced the intervention of administrative power.

An industry veteran told Cypress that the revised plan clearly demonstrated the “revolutionary price reform” information, especially regarding the revision of relevant policies for low-priced drugs, and represented the direction of future reforms.

Explaining the New Deal in Guangdong Province in three sentences, the low-cost medicine policy is a good example, the hospital drug sales price is moving forward, the NDRC system drug price control is faded out, and the bidding is played. The specific performance is as follows:

1. The NDRC's system of drug price control is intended to stop or be invited to play.

The revision plan adjusted the collection mechanism of the market price data source. The prices of the successful bids for the same medicines from different manufacturers across the country and the current purchase price in Guangdong were revised by the “provincial health department in charge of provincial price departments” and revised to be “collected by provincial health and family planning authorities”.

Adjust the market price calculation agency. The market price was modified by the original “Provincial Price Administration Department to be formulated by the provincial health authority” to be calculated by the provincial drug trading agency and reviewed by the Provincial Department of Development and Reform and the Provincial Health and Family Planning Authority, the Provincial Human Resources and Social Security Department.”

2, drug prices released control, but still carry "Yao" forward

Although the revised program "adjusted the maximum temporary retail price calculation agency. The original "provincial price department" calculated according to the prescribed rate of change for each transaction price of the highest temporary retail price was revised by the "medical institutions" according to the price of each transaction transaction Calculate the temporary retail price of the traded product.

However, due to the restrictions on relevant drug policy documents issued in the past, in particular, relevant policy documents issued by the relevant ministries and commissions in the country such as the “zero-judgment policy, the policy of increasing the rate of 15% of the price increase rate, and the maximum retail price control” are currently in the country. The level has not been revised or repealed. Guangdong's reforms are still subject to the relevant policies of the previous period.

In the program, the retail price control of medical institutions is still restricted. For example, the plan proposes that “the medical institution calculates the temporary retail price of the transaction type according to the transaction price of each transaction. (The medical institution that sells with zero sales, the transaction price is (Temporary retail price). The temporary retail price shall not exceed the maximum rate and maximum retail price stipulated by the provincial development and reform department.

3, low-cost drug reform is a good example

The price control of low-priced medicines and other categories is basically in a state of complete liberalization, but it is also affected. The amendments proposed that “low-priced drugs are not included in the market price; clinically necessary and difficult-to-purchase varieties are the highest retail price of the government’s pricing as the market price, and the market adjustment price is not set as the market price.